Intellectual Property India Publishes Patent Application for 'Recombinant Opcml Fusion Protein Optimizing Opcml D1 Domain Homodimerisation And Methods Of Use For Cancer Treatment' Filed by Papyrus Therapeutics Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517049936 A) filed by Papyrus Therapeutics Inc., Solana Beach, U.S.A., on May 23, for 'recombinant opcml fusion protein optimizing opcml d1 domain homodimerisation and methods of use for cancer treatment.'

Inventor(s) include Gabra, Hani; and Blake, Paul.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "Presented herein is a recombinant OPCML-Fc fusion protein molecule and methods of its use in cancer treatment where the Fc portion of the fusion protein molecule is only the CH2CH3 portion and lacks the hinge region containing the disulfide bri...